A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension

Is this Study for You?

Let's Get Started!



Type of Study



Childrens Hospital Colorado

Principal Investigator
Photograph of David Ivy,  MD

David Ivy, MD

Study ID

Protocol Number: 19-3001

More information available at ClinicalTrials.gov: NCT04175600

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers